• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

利用定制的寡核苷酸 RNA 抑制剂有效降低 SARS-CoV-2 RNA 水平。

Effective Reduction of SARS-CoV-2 RNA Levels Using a Tailor-Made Oligonucleotide-Based RNA Inhibitor.

机构信息

Selecta Biotech SE, Istrijska 6094/20, 841 07 Bratislava, Slovakia.

Biomedical Research Center, Department of Nanobiology, Cancer Research Institute, Slovak Academy of Sciences, Dubravska Cesta 9, 845 05 Bratislava, Slovakia.

出版信息

Viruses. 2022 Mar 25;14(4):685. doi: 10.3390/v14040685.

DOI:10.3390/v14040685
PMID:35458415
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9029688/
Abstract

In only two years, the coronavirus disease 2019 (COVID-19) pandemic has had a devastating effect on public health all over the world and caused irreparable economic damage across all countries. Due to the limited therapeutic management of COVID-19 and the lack of tailor-made antiviral agents, finding new methods to combat this viral illness is now a priority. Herein, we report on a specific oligonucleotide-based RNA inhibitor targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It displayed remarkable spontaneous cellular uptake, >94% efficiency in reducing RNA-dependent RNA polymerase (RdRp) RNA levels in transfected lung cell lines, and >98% efficiency in reducing SARS-CoV-2 RNA levels in samples from patients hospitalized with COVID-19 following a single application.

摘要

在短短两年内，2019 年冠状病毒病（COVID-19）大流行对全世界的公共卫生造成了毁灭性的影响，并给所有国家造成了无法弥补的经济损失。由于 COVID-19 的治疗管理有限，而且缺乏定制的抗病毒药物，因此现在当务之急是寻找新的方法来对抗这种病毒性疾病。在此，我们报告了一种针对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的特定基于寡核苷酸的 RNA 抑制剂。它显示出显著的自发细胞摄取能力，在转染的肺细胞系中，将 RNA 依赖性 RNA 聚合酶（RdRp）RNA 水平降低 94%以上，并且在 COVID-19 住院患者的样本中，单次应用后将 SARS-CoV-2 RNA 水平降低 98%以上。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df3/9029688/92e3892e9c14/viruses-14-00685-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df3/9029688/45a0afd649fa/viruses-14-00685-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df3/9029688/0aea0a26fdfe/viruses-14-00685-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df3/9029688/5ee3ea9b8bdd/viruses-14-00685-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df3/9029688/22f7a419a006/viruses-14-00685-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df3/9029688/92e3892e9c14/viruses-14-00685-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df3/9029688/45a0afd649fa/viruses-14-00685-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df3/9029688/0aea0a26fdfe/viruses-14-00685-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df3/9029688/5ee3ea9b8bdd/viruses-14-00685-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df3/9029688/22f7a419a006/viruses-14-00685-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3df3/9029688/92e3892e9c14/viruses-14-00685-g005.jpg

相似文献

1
Effective Reduction of SARS-CoV-2 RNA Levels Using a Tailor-Made Oligonucleotide-Based RNA Inhibitor.利用定制的寡核苷酸 RNA 抑制剂有效降低 SARS-CoV-2 RNA 水平。
Viruses. 2022 Mar 25;14(4):685. doi: 10.3390/v14040685.
2
RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target.SARS-CoV-2 的 RNA 依赖性 RNA 聚合酶作为治疗靶点。
J Med Virol. 2021 Jan;93(1):300-310. doi: 10.1002/jmv.26264. Epub 2020 Jul 19.
3
Identifying Small-Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase by Establishing a Fluorometric Assay.通过建立荧光测定法鉴定 SARS-CoV-2 RNA 依赖性 RNA 聚合酶的小分子抑制剂。
Front Immunol. 2022 Apr 7;13:844749. doi: 10.3389/fimmu.2022.844749. eCollection 2022.
4
TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).TMPRSS2 和 RNA 依赖性 RNA 聚合酶是治疗由 SARS-CoV-2 变异株（B.1.1.7 和 B.1.351）引起的 COVID-19 的有效治疗靶点。
Microbiol Spectr. 2021 Sep 3;9(1):e0047221. doi: 10.1128/Spectrum.00472-21. Epub 2021 Aug 11.
5
2-((1H-indol-3-yl)thio)-N-phenyl-acetamides: SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.2-((1H-吲哚-3-基)硫代)-N-苯基乙酰胺：SARS-CoV-2 依赖 RNA 的 RNA 聚合酶抑制剂。
Antiviral Res. 2021 Dec;196:105209. doi: 10.1016/j.antiviral.2021.105209. Epub 2021 Nov 18.
6
5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis.5-碘尿苷抑制 SARS-CoV-2 病毒的 RNA 合成。
Antiviral Res. 2022 Feb;198:105254. doi: 10.1016/j.antiviral.2022.105254. Epub 2022 Jan 29.
7
Recognition of plausible therapeutic agents to combat COVID-19: An omics data based combined approach.识别有潜力对抗 COVID-19 的治疗药物：基于组学数据的综合方法。
Gene. 2021 Mar 1;771:145368. doi: 10.1016/j.gene.2020.145368. Epub 2020 Dec 17.
8
RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.RNA 依赖性 RNA 聚合酶作为 COVID-19 药物发现的靶标。
SLAS Discov. 2020 Dec;25(10):1141-1151. doi: 10.1177/2472555220942123. Epub 2020 Jul 13.
9
Molecular and Structural Analysis of Specific Mutations from Saudi Isolates of SARS-CoV-2 RNA-Dependent RNA Polymerase and their Implications on Protein Structure and Drug-Protein Binding.SARS-CoV-2 RNA 依赖的 RNA 聚合酶的沙特分离株特定突变的分子和结构分析及其对蛋白质结构和药物-蛋白质结合的影响。
Molecules. 2022 Oct 1;27(19):6475. doi: 10.3390/molecules27196475.
10
An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges.针对 COVID-19 治疗的靶向 RNA 依赖性 RNA 聚合酶抑制剂的最新进展：前景与挑战。
Biochem Pharmacol. 2022 Nov;205:115279. doi: 10.1016/j.bcp.2022.115279. Epub 2022 Oct 6.

引用本文的文献

1
ASP210: a potent oligonucleotide-based inhibitor effective against TKI-resistant CML cells.ASP210：一种有效的基于寡核苷酸的抑制剂，可有效对抗 TKI 耐药的 CML 细胞。
Am J Physiol Cell Physiol. 2024 Jul 1;327(1):C184-C192. doi: 10.1152/ajpcell.00188.2024. Epub 2024 Jun 3.

本文引用的文献

1
Small Drugs, Huge Impact: The Extraordinary Impact of Antisense Oligonucleotides in Research and Drug Development.小药物，大影响：反义寡核苷酸在研究和药物开发中的非凡影响。
Molecules. 2022 Jan 15;27(2):536. doi: 10.3390/molecules27020536.
2
Inhibition of SARS-CoV-2 by Targeting Conserved Viral RNA Structures and Sequences.通过靶向保守的病毒RNA结构和序列抑制严重急性呼吸综合征冠状病毒2
Front Chem. 2021 Dec 23;9:802766. doi: 10.3389/fchem.2021.802766. eCollection 2021.
3
A tale of two antiviral targets - and the COVID-19 drugs that bind them.
两个抗病毒靶点的故事——以及与之结合的新冠病毒药物。
Nat Rev Drug Discov. 2022 Jan;21(1):3-5. doi: 10.1038/d41573-021-00202-8.
4
Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review.重新利用药理学药物治疗 COVID-19 的潜力：文献综述。
Respir Res. 2021 Nov 27;22(1):304. doi: 10.1186/s12931-021-01885-8.
5
Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis.公共卫生措施在降低新冠病毒发病率、SARS-CoV-2 传播率和新冠死亡率方面的有效性：系统评价和荟萃分析。
BMJ. 2021 Nov 17;375:e068302. doi: 10.1136/bmj-2021-068302.
6
Antisense oligonucleotide activity in tumour cells is influenced by intracellular LBPA distribution and extracellular vesicle recycling.反义寡核苷酸在肿瘤细胞中的活性受到细胞内 LBPA 分布和细胞外囊泡回收的影响。
Commun Biol. 2021 Nov 1;4(1):1241. doi: 10.1038/s42003-021-02772-0.
7
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape.COVID-19 疫苗研发进展：病毒、疫苗和变体与疗效、有效性和逃逸。
Nat Rev Immunol. 2021 Oct;21(10):626-636. doi: 10.1038/s41577-021-00592-1. Epub 2021 Aug 9.
8
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗策略：对3期候选疫苗的全面综述
NPJ Vaccines. 2021 Feb 22;6(1):28. doi: 10.1038/s41541-021-00292-w.
9
Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach.利用计算方法分析 SARS-CoV-2 RNA 依赖性 RNA 聚合酶作为潜在的治疗药物靶标。
J Transl Med. 2020 Jul 7;18(1):275. doi: 10.1186/s12967-020-02439-0.
10
Nuclear and Cytoplasmatic Quantification of Unconjugated, Label-Free Locked Nucleic Acid Oligonucleotides.未结合、无标记锁核酸寡核苷酸的核质定量分析。
Nucleic Acid Ther. 2020 Feb;30(1):4-13. doi: 10.1089/nat.2019.0810. Epub 2019 Oct 16.